Asandeutertinib vs Rezivertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Asandeutertinib
Marketed by TYK Medicines, Inc.
NCT05146219 · Phase 2 · completed
The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06672068 (registry estimate)
Reported efficacy
Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)
Result source: NCT05146219
Rezivertinib
Marketed by Beta Pharma, Inc.
NCT03866499 · Phase 3 · status unknown
This trial randomized 369 patients to BPI-7711 or active-controlled gefitinib with full blinding of participants, care providers, investigators, and outcome assessors, testing a hard clinical endpoint (progression-free survival) that is standard for regulatory approval in NSCLC. The primary comparison was statistically significant and favored BPI-7711, with a nearly doubled median PFS and a strong hazard ratio, supporting confidence in the result.
Next expected readout: December 2030 · NCT06955325 (registry estimate)
Reported efficacy
Progression-free survival (up to approximately 16 months): REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 (met)
Result source: NCT03866499
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asandeutertinib | Rezivertinib |
|---|---|---|
| PFS, median | —Trial running · NCT05382728 | —Trial running · NCT06955325 |
| OS, median | —Trial running · NCT05382728 | —Trial running · NCT06955325 |
| ORR | —Trial running · NCT05382728 | —Trial running · NCT06955325 |
| Duration of response, median | —Trial running · NCT05382728 | —Trial running · NCT06955325 |
PFS, median
- Asandeutertinib
- —Trial running · NCT05382728
- Rezivertinib
- —Trial running · NCT06955325
OS, median
- Asandeutertinib
- —Trial running · NCT05382728
- Rezivertinib
- —Trial running · NCT06955325
ORR
- Asandeutertinib
- —Trial running · NCT05382728
- Rezivertinib
- —Trial running · NCT06955325
Duration of response, median
- Asandeutertinib
- —Trial running · NCT05382728
- Rezivertinib
- —Trial running · NCT06955325
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · Rezivertinib's landscape